PMID: 1203853Jul 1, 1975Paper

Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer

Cancer
S E JonesS E Salmon

Abstract

Fifty-five consecutive women with advanced breast cancer were treated with a combination of adriamycin (40 mg/m2 administered intravenously on day 1) and cyclophosphamide (200 mg/m2/day given orally in divided doses for 4 days on days 3-6). Courses were repeated at 21-28-day intervals. The mean age for the 55 patients was 55 years (range, 37-77 years); 20% of the patients were 65 years or older. All patients were evaluable. Objective response (at least a 50% decrease in the size of all measurable lesions lasting for at least 1 month) was noted in 40 (80%) of the 50 patients who received an adequate trial of chemotherapy (a minimum of two courses). Six of the 40 responses observed were complete. The median duration of response was 10 months. Actuarial survival for the entire group of 55 patients was 80% at 6 months after initiating chemotherapy and 70% at 12 months. Survival for the 40 responding patients was 95% at 6 months and 80% at 12 months. Response rates by site of involvement were: soft tissue, 20/25 (80%); lymph node, 15/19 (79%); bone, 21/25 (84%); lung, 15/18 (83%); pleural effusion, 6/8 (75%); and liver, 7/10 (70%). Eighty-three percent of the responses were apparent after two courses of treatment and 98% were appare...Continue Reading

References

Oct 1, 1974·Annals of Internal Medicine·J J RinehartS P Balcerzak
Aug 1, 1973·Cancer·E A LefrakJ A Gottlieb
Feb 1, 1974·Annals of Internal Medicine·R H Blum, S K Carter
Dec 1, 1972·Cancer·B Fisher
Feb 9, 1974·British Medical Journal·G P CanellosR C Young

❮ Previous
Next ❯

Citations

Jan 1, 1982·Cancer Chemotherapy and Pharmacology·S B Kaye
Jan 1, 1994·Breast Cancer Research and Treatment·M MillwardB Cantwell
Jan 1, 1994·Cancer Chemotherapy and Pharmacology·Y AraiC Kido
Jan 1, 1990·Journal of Cancer Research and Clinical Oncology·T OkinoK Ohgaki
Jan 1, 1991·Journal of Cancer Research and Clinical Oncology·M LopezL Di Lauro
Jan 1, 1984·Breast Cancer Research and Treatment·M E Lippman
Nov 1, 1987·Breast Cancer Research and Treatment·L FerrariG Bonadonna
Dec 1, 1985·Journal of Steroid Biochemistry·M R SertoliR Rosso
Feb 8, 2000·International Journal of Radiation Oncology, Biology, Physics·B J HaylockK S Wilson
Dec 8, 1977·The New England Journal of Medicine·S S LeghaG R Blumenschein
Dec 27, 1979·The New England Journal of Medicine·J C DeanK S Griffith
Jan 10, 1980·The New England Journal of Medicine·I C Henderson, G P Canellos
Jun 11, 1999·American Journal of Clinical Oncology·A I ShamseddineN S El Saghir
Nov 1, 1978·British Journal of Haematology·H P LohrmannH Heimpel
Mar 1, 1992·Journal of Veterinary Internal Medicine·G E MauldinR E Matus
Apr 3, 1976·British Medical Journal·C BrambillaG Bonadonna
Jul 9, 1977·British Medical Journal
Jan 1, 1979·Acta Radiologica: Oncology, Radiation, Physics, Biology·W MattssonC E Lindholm
Apr 1, 1977·Acta Radiologica: Therapy, Physics, Biology·W MattssonB Astedt
Jan 1, 1986·Cancer Investigation·L E Damon, E C Cadman
Mar 1, 1978·International Journal of Radiation Oncology, Biology, Physics·S K Carter
Mar 1, 1977·International Journal of Radiation Oncology, Biology, Physics·S A AristizabalM L Boone
Nov 1, 1976·International Journal of Radiation Oncology, Biology, Physics·E G MayerS A Aristizabal
Aug 7, 2009·The Breast : Official Journal of the European Society of Mastology·R C F LeonardS Oliveros
Apr 1, 1978·Toxicology and Applied Pharmacology·P C MerkerE P Richardson
Aug 27, 1977·The Medical Journal of Australia·I S Russell, W J Moon
Dec 1, 1985·Cancer Treatment Reviews·R E Coleman, R D Rubens
Jul 1, 1991·Current Problems in Cancer·M A BookmanR M Scher
Feb 1, 1978·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D W YesairI Wodinsky
May 1, 1979·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F GiulianiG Savi
Sep 1, 1982·Journal of Surgical Oncology·A E AwrichW S Fletcher
Jun 1, 1982·Cancer Treatment Reviews·D V UnverferthS P Balcerzak

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.